Exo Therapeutics

Exo Therapeutics

  • Founded: 2020
  • Location: Watertown, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Autoimmune diseases
  • Drug types: ONC, IMM
  • Lead product: Undisclosed
  • Product link: https://exo-therapeutics.com/pipeline/
  • Funding: $78M B Oct 2021; $25M A Dec 2020



job board

Short description:

Small Molecule Drug Discovery

Drug notes:

4+ additional undisclosed programs RD oncology, solid tumors, fibrotic diseases, undisclosed

Long description:

Exo Therapeutics is a small molecule drug discovery company addressing intractable pharmaceutical targets. Most small molecules are designed to bind the active site of an enzyme; however, many active sites are inaccessible or are similar to non-target enzymes. Exo Therapeutics is targeting exosites, which are distal substrate-enzyme sites that occur widely across the proteome. Exo uses their ExoSight platform to develop a pipeline of potent drug candidates that reprogram enzyme activity for oncology, inflammation and other diseases. Exo aims to expand the druggable universe with exosites that represent ~30% of known target space. Through the use of CryoEM structures, structural biology and protein engineering, Exo has built proprietary capabilities for systematized ligand discovery.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com